Why is Brooks Lab. falling/rising?

As of 22-Sep, Brooks Laboratories Ltd is experiencing a decline in its stock price, currently at 147.55, reflecting a decrease of 0.4 or 0.27%. The stock has been underperforming recently, with a consecutive fall over the last five days resulting in a total decline of 7.2%. Despite outperforming its sector by 0.81% today, the stock's delivery volume has significantly decreased by 65.97% compared to the five-day average, indicating falling investor participation. While the company reported very positive results with a 97.76% growth in net profit and has shown consistent positive results over the last three quarters, its long-term fundamental strength is weak, highlighted by an average Return on Equity (ROE) of 0% and a poor EBIT to Interest ratio of -3.82.
In the broader market context, the stock's recent performance contrasts sharply with the Sensex, which has gained 0.46% over the past week. Although Brooks Laboratories has shown a modest gain of 1.34% over the past month, its year-to-date performance is significantly worse, with a decline of 20.22% compared to the Sensex's increase of 5.15%. The stock's valuation is considered very expensive with a Price to Book Value of 4.4, despite trading at a discount compared to its peers. This combination of weak long-term growth prospects and high valuation metrics contributes to the stock's downward pressure in the market.